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Introduction {#art40851-sec-0005}
============

Psoriatic arthritis (PsA) is a chronic, systemic inflammatory arthritis of the peripheral joints and axial skeleton that is commonly associated with psoriasis [1](#art40851-bib-0001){ref-type="ref"}. Clinical manifestations include dactylitis, enthesitis, and nail changes, as well as joint erosions frequently seen on radiographs [1](#art40851-bib-0001){ref-type="ref"}. PsA occurs in up to 30% of patients with psoriasis [2](#art40851-bib-0002){ref-type="ref"}. The annual incidence of PsA in patients with psoriasis has been reported to be 1--3% [3](#art40851-bib-0003){ref-type="ref"}, [4](#art40851-bib-0004){ref-type="ref"}, [5](#art40851-bib-0005){ref-type="ref"}.

Early treatment of PsA may help prevent the impaired function and deformities caused by joint destruction [6](#art40851-bib-0006){ref-type="ref"}, [7](#art40851-bib-0007){ref-type="ref"}, [8](#art40851-bib-0008){ref-type="ref"}. Agents used to treat PsA include disease‐modifying antirheumatic drugs (DMARDs) such as methotrexate and tumor necrosis factor (TNF) inhibitors [9](#art40851-bib-0009){ref-type="ref"}, [10](#art40851-bib-0010){ref-type="ref"}. Additional agents that have recently been approved for use in PsA include biologic inhibitors of the interleukin‐12 (IL‐12)/IL‐23 and IL‐17 pathways [11](#art40851-bib-0011){ref-type="ref"}, [12](#art40851-bib-0012){ref-type="ref"}, [13](#art40851-bib-0013){ref-type="ref"} and small molecule inhibitors of janus kinase [14](#art40851-bib-0014){ref-type="ref"} and phosphodiesterase 4 [15](#art40851-bib-0015){ref-type="ref"}. Although methotrexate is widely used to treat PsA and is approved by the US Food and Drug Administration (FDA) for use in psoriasis, it is not approved by the FDA for the treatment of PsA. Therefore, there is a need to better understand its efficacy in PsA [16](#art40851-bib-0016){ref-type="ref"}, [17](#art40851-bib-0017){ref-type="ref"}, [18](#art40851-bib-0018){ref-type="ref"}.

Prior trials comparing methotrexate with a biologic agent included patients who were inadequate responders to methotrexate [19](#art40851-bib-0019){ref-type="ref"}, thus limiting the ability to clearly understand the efficacy of methotrexate in comparison with an established biologic therapy in methotrexate‐naive patients. In the Remicade Study in Psoriatic Arthritis Patients of Methotrexate‐Naive Disease (RESPOND) trial [20](#art40851-bib-0020){ref-type="ref"}, investigators studied the efficacy of methotrexate in methotrexate‐naive patients, but it was an open‐label study that compared methotrexate with infliximab in combination with methotrexate, obscuring the ability to directly compare the efficacy of methotrexate and infliximab as monotherapies. The Methotrexate in Psoriatic Arthritis (MIPA) study, a randomized clinical trial comparing methotrexate with placebo in methotrexate‐naive patients, failed to demonstrate statistically significant differences between the 2 study arms at 24 weeks [21](#art40851-bib-0021){ref-type="ref"}. However, the overall findings were inconclusive, possibly because of a high dropout rate and use of a submaximal methotrexate target dosage of 15 mg/week [21](#art40851-bib-0021){ref-type="ref"}.

The efficacy of TNF inhibitors has been demonstrated in PsA [22](#art40851-bib-0022){ref-type="ref"}, [23](#art40851-bib-0023){ref-type="ref"}, [24](#art40851-bib-0024){ref-type="ref"}, [25](#art40851-bib-0025){ref-type="ref"}, [26](#art40851-bib-0026){ref-type="ref"}, [27](#art40851-bib-0027){ref-type="ref"}, but the benefit of combining methotrexate and TNF inhibitors remains unclear. In rheumatoid arthritis, the Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO) study [28](#art40851-bib-0028){ref-type="ref"} (and analogous trials with other TNF inhibitors) have established that methotrexate used in combination with a TNF inhibitor increases the efficacy of the TNF inhibitor. No comparable study has been conducted in PsA, and results of observational studies have suggested that, unlike in rheumatoid arthritis, no additional efficacy is added by combining methotrexate with a TNF inhibitor in PsA [29](#art40851-bib-0029){ref-type="ref"}, [30](#art40851-bib-0030){ref-type="ref"}.

We therefore undertook the current randomized, controlled trial to examine the comparative efficacy of methotrexate monotherapy relative to TNF inhibitor monotherapy in methotrexate‐naive patients with PsA early in the course of their disease. This trial also assessed the effect of combining methotrexate with a TNF inhibitor for the treatment of PsA in this patient population.

Patients and methods {#art40851-sec-0006}
====================

 {#art40851-sec-0007}

### Study design and population {#art40851-sec-0008}

The Study of Etanercept and Methotrexate in Subjects with Psoriatic Arthritis (SEAM‐PsA) trial was a 48‐week phase III, multicenter, randomized, double‐blind international study [31](#art40851-bib-0031){ref-type="ref"}. Following the 48‐week double‐blind period, there was a 30‐day safety follow‐up period. Study patients were adults age ≥18 years with active PsA (based on the Classification Criteria for Psoriatic Arthritis [32](#art40851-bib-0032){ref-type="ref"}) who were naive to treatment with etanercept and other biologic agents, and had no prior use of methotrexate for PsA. Prior treatment with methotrexate was allowed for psoriasis if discontinuation had not been due to toxicity or intolerance, and if the methotrexate had been discontinued ≥6 months prior to initiation of the investigational product. Patients had to have 3 tender joints and 3 swollen joints (based on 68‐ and 66‐joint counts, respectively) at screening and at baseline, and an active psoriatic skin lesion that was ≥2 cm in diameter. For patients who were receiving nonsteroidal antiinflammatory drugs (NSAIDs), the dose had to be stable ≥2 weeks prior to initiation of the investigational product. For patients receiving oral corticosteroids, the dose had to be stable (not to exceed the equivalent of 10 mg prednisone per day) ≥4 weeks prior to initiation of the investigational product (for a complete description of the patient inclusion and exclusion criteria, see [Supplementary Methods](#art40851-sup-0003){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40851/abstract>).

Patients were enrolled in the study at 124 hospital centers or clinics in 17 countries (for a list of the investigators and countries in which the study was conducted, see [Supplementary Methods](#art40851-sup-0003){ref-type="supplementary-material"} at <http://onlinelibrary.wiley.com/doi/10.1002/art.40851/abstract>). Patients were randomized 1:1:1 to 1 of 3 treatment arms, as follows: oral methotrexate (target dose 20 mg) plus subcutaneous placebo given weekly, subcutaneous etanercept (target dose 50 mg) plus oral placebo given weekly, or subcutaneous etanercept (target dose 50 mg) plus oral methotrexate (target dose 20 mg) given weekly. At or after week 24, patients with an inadequate response to treatment (i.e., showing \<20% improvement from baseline in tender joint counts and \<20% improvement from baseline in swollen joint counts) received rescue therapy with etanercept plus methotrexate until week 48. Patients who were withdrawn or removed were not replaced. Patients were randomized via an interactive voice‐response system, based on a computer‐generated randomization schedule that was prepared by the study sponsor before the start of the trial. Each patient was assigned a single, unique randomization number. Treatment assignments were maintained within the interactive voice‐response system.

Both patients and investigators were blinded with regard to the randomized treatment assignments. Original treatment assignments remained blinded until patients reached week 48 or had an early termination visit (whichever occurred first). Treatment assignment was only unblinded when knowledge of treatment was essential to further patient care. Blinding was achieved by using matching prefilled syringes for the etanercept and injectable placebo administrations, and by using matching capsules for the methotrexate and oral placebo administrations.

Etanercept is a dimeric fusion protein (comprising the extracellular ligand‐binding domain of the human TNF p75 receptor linked to the Fc portion of human IgG1) that inhibits the activity of TNFα and TNFβ [33](#art40851-bib-0033){ref-type="ref"}. For the SEAM‐PsA trial, etanercept was manufactured and provided by Immunex (a subsidiary of Amgen Inc.) in single‐use, prefilled 1‐ml syringes. Etanercept was administered at a dosage of 50 mg/week by subcutaneous injection, as recommended in the US prescribing information for use of etanercept in PsA [33](#art40851-bib-0033){ref-type="ref"}.

The first dose of etanercept was administered at the study site, and subsequent injections were administered by the patient or a caregiver. Methotrexate, supplied as 2.5‐mg tablets in capsules (for blinding purposes), was initiated at a dosage of 10 mg/week and titrated up to 20 mg/week over a 4‐week period. If patients developed a toxic reaction to methotrexate, the methotrexate dosage could be reduced to as low as 10 mg/week. Folic acid was administered at 5--7 mg/week. Patients entering the study taking oral corticosteroids had to remain on a stable dose up to week 24. Those taking acetaminophen, narcotic analgesics, or NSAIDs had to remain on a stable dose up to week 24 and could not take these agents within 12 hours (24 hours for oxycontin) before a scheduled study visit.

### Registration and ethics review {#art40851-sec-0009}

The SEAM‐PsA study has been completed, and is registered at <https://ClinicalTrials.gov> . The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent, and each participating site obtained protocol approval by an institutional review board. A data monitoring committee did not oversee this study.

### Study outcome measures {#art40851-sec-0010}

Outcomes were measured at baseline and at weeks 4, 8, 12, 16, 24, 36, and 48. The primary end point was achievement of ≥20% improvement in the American College of Rheumatology response (ACR20) criteria [34](#art40851-bib-0034){ref-type="ref"} at week 24. (For detailed descriptions and scales for all of the outcome measures used, see [Supplementary Table 1](#art40851-sup-0003){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40851/abstract>.) The key secondary end point was the Minimal Disease Activity (MDA) response [35](#art40851-bib-0035){ref-type="ref"} at week 24. Secondary end points included the ACR20 and MDA response rates analyzed at other time points, as well as ACR50 and ACR70 response rates analyzed at all time points.

Additional end points, assessed at weeks 24 and 48, included the following: Very Low Disease Activity (VLDA) response [35](#art40851-bib-0035){ref-type="ref"}, Psoriatic Arthritis Disease Activity Score (PASDAS) [36](#art40851-bib-0036){ref-type="ref"}, Disease Activity Index for Psoriatic Arthritis (DAPSA) score [37](#art40851-bib-0037){ref-type="ref"}, change from baseline in both the Leeds Dactylitis Index (LDI) [38](#art40851-bib-0038){ref-type="ref"} and the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index [39](#art40851-bib-0039){ref-type="ref"}, dermatologic end points of the percentage of psoriasis‐affected body surface area (BSA) [40](#art40851-bib-0040){ref-type="ref"}, the static Physician\'s Global Assessment (sPGA) of psoriasis [41](#art40851-bib-0041){ref-type="ref"}, and modified Nail Psoriasis Severity Index (mNAPSI) [42](#art40851-bib-0042){ref-type="ref"}, and patient‐reported outcomes from the Health Assessment Questionnaire disability index (HAQ DI) [43](#art40851-bib-0043){ref-type="ref"} and the 36‐item Short Form (SF‐36) Health Survey [44](#art40851-bib-0044){ref-type="ref"}.

Radiographic end points included change from baseline in radiographic progression scores using the van der Heijde modification of the total Sharp score (SHS) [45](#art40851-bib-0045){ref-type="ref"}, and rates of radiographic nonprogression at weeks 24 and 48. Radiographs of the hands and feet were obtained from patients locally and read centrally by 2 independent readers to assess erosions and joint space narrowing.

Safety analyses examined the incidence of adverse events, serious adverse events, and adverse events leading to discontinuation of the investigational product at weeks 24 and 48.

### Statistical analysis {#art40851-sec-0011}

For the SEAM‐PsA study, we estimated that a sample size of 840 patients would provide a marginal power of \>90% to detect treatment differences in the ACR20 response at week 24 between the etanercept‐containing arms and the methotrexate monotherapy arm, at a 2‐sided significance level of 0.025. This estimate assumed a randomization ratio of 1:1:1 to the 3 study arms (adjusting for an anticipated 10% dropout rate) and assumed an ACR20 response rate of 65% for the etanercept plus methotrexate combination arm, 60% for the etanercept monotherapy arm, and 44% for the methotrexate monotherapy arm. A sample size of 840 patients was also estimated to provide a marginal power of \>90% to detect treatment differences in the MDA response at week 24 between the etanercept‐containing arms and the methotrexate monotherapy arm, at a 2‐sided significance level of 0.025, assuming response rates of 35% for the etanercept plus methotrexate combination therapy arm, 30% for the etanercept monotherapy arm, and 15% for the methotrexate monotherapy arm. These assumed response rates for the ACR20 and MDA responses were estimates based on data from previous studies [21](#art40851-bib-0021){ref-type="ref"}, [22](#art40851-bib-0022){ref-type="ref"}, [29](#art40851-bib-0029){ref-type="ref"}, [35](#art40851-bib-0035){ref-type="ref"}, [46](#art40851-bib-0046){ref-type="ref"} and on the assumption that generally higher responses than those reported in the literature would occur in the SEAM‐PsA trial since it enrolled patients whose disease course was anticipated to be in a relatively early phase and who were naive to treatment with biologics and methotrexate for PsA.

Analyses were conducted using SAS version 9.4 (SAS Institute). The main analyses of the primary and key secondary end points were based on the full analysis set, which included all randomized patients analyzed according to randomization assignment (intent‐to‐treat analysis). Missing data were imputed as nonresponder data. The treatment differences between etanercept plus methotrexate combination therapy and methotrexate monotherapy, and between etanercept monotherapy and methotrexate monotherapy were tested in a Bonferroni‐based gatekeeping chain procedure [47](#art40851-bib-0047){ref-type="ref"} to control the family‐wise, 2‐sided Type I error rate at 0.05 (see [Supplementary Figure 1](#art40851-sup-0001){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40851/abstract>). Between‐treatment comparisons were adjusted using the Cochran‐Mantel‐Haenszel test, with baseline body mass index status (≤30 kg/m^2^ or \>30 kg/m^2^) and prior treatment with a non--biologic DMARD being used as stratification factors. The risk difference between groups was estimated using the Mantel‐Haenszel estimate of common risk difference (using the same stratification factors mentioned above).

Efficacy end points other than the primary and key secondary end points were analyzed as observed and not adjusted for multiplicity; therefore, *P* values are unadjusted and considered descriptive. Safety end points were summarized descriptively based on the safety analysis set, which included patients who received ≥1 dose of active investigational product. Patients were analyzed according to actual treatment received.

Results {#art40851-sec-0012}
=======

Between March 3, 2015 and July 7, 2017, a total of 851 patients (of 1,080 screened) were enrolled in the SEAM‐PsA trial (229 patients did not meet the eligibility criteria) and randomized to receive a treatment (Figure [1](#art40851-fig-0001){ref-type="fig"}). The last patient completed the study on July 6, 2018. Of the 851 enrolled patients, 284 were randomized to receive methotrexate monotherapy, 284 to receive etanercept monotherapy, and 283 to receive methotrexate plus etanercept (combination therapy) (Figure [1](#art40851-fig-0001){ref-type="fig"}). Of the 851 patients, 44% were from North America, 27% from Europe, 16% from Latin America, 9% from Russia, and 4% from South Africa. The number of patients who received their intended treatment was 282 (99.3%) in the methotrexate monotherapy arm, 284 (100%) in the etanercept monotherapy arm, and 282 (99.6%) in the combination therapy arm. A total of 691 patients (81.2%) completed the trial. The most common reason for study discontinuation was withdrawal of consent. The primary end point was analyzed using the full analysis set of 851 randomized patients.

![Diagram of patient allocation.](ART-71-1112-g001){#art40851-fig-0001}

The 3 treatment arms were generally balanced with respect to baseline demographic and disease characteristics (Table [1](#art40851-tbl-0001){ref-type="table"}). Most patients were white (90.7%), and the mean ± SD age was 48.4 ± 13.1 years. The duration of PsA was a mean ± SD 3.2 ± 6.3 years (median 0.6 years); overall, 56% of patients had a disease duration of ≤2 years. In total, 12.6% of the patients had received prior treatment with a nonbiologic DMARD (42 patients \[5%\] had received methotrexate prior to the study). Prior treatment with a nonbiologic DMARD occurred in 13.4%, 9.2%, and 15.2% of patients in the methotrexate monotherapy, etanercept monotherapy, and combination arms, respectively (Table [1](#art40851-tbl-0001){ref-type="table"}). From weeks 4 to 24, patients in both of the methotrexate‐containing treatment arms achieved and maintained a mean methotrexate dose of \>18.8 mg (median 20 mg) (average weekly doses are listed in [Supplementary Table 2](#art40851-sup-0003){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40851/abstract>). The percentage of patients who received rescue therapy at or after week 24 was 24.3% in the methotrexate monotherapy arm, 16.2% in the etanercept monotherapy arm, and 12.7% in the combination therapy arm.

###### 

Baseline demographic and disease characteristics of the patients in each treatment group[a](#art40851-note-0006){ref-type="fn"}

                                                                                 Methotrexate monotherapy (n = 284)   Etanercept monotherapy (n = 284)   Combination therapy (n = 283)
  ------------------------------------------------------------------------------ ------------------------------------ ---------------------------------- -------------------------------
  Age, mean ± SD years                                                           48.7 ± 13.1                          48.5 ± 13.5                        48.1 ± 12.7
  Sex, no. (%) female                                                            160 (56.3)                           133 (46.8)                         139 (49.1)
  Race, no. (%) white                                                            255 (89.8)                           252 (88.7)                         265 (93.6)
  Duration of PsA, mean ± SD years (no. assessed)                                3.6 ± 6.8 (231)                      3.1 ± 6.0 (222)                    3.0 ± 6.0 (231)
  Prior use of nonbiologic DMARD, no. (%)                                        38 (13.4)                            26 (9.2)                           43 (15.2)
  Body mass index, mean ± SD kg/m^2^ (no. assessed)                              30.6 ± 7.1 (284)                     30.4 ± 6.6 (283)                   30.0 ± 6.7 (283)
  ≤30 kg/m^2^, no. (%)                                                           146 (51.4)                           153 (53.9)                         160 (56.5)
  \>30 kg/m^2^, no. (%)                                                          138 (48.6)                           130 (45.8)                         123 (43.5)
  Swollen joint count (of 66 joints), mean ± SD (no. assessed)                   12.9 ± 9.9 (284)                     11.5 ± 9.6 (283)                   11.2 ± 9.1 (282)
  Tender joint count (of 68 joints), mean ± SD (no. assessed)                    20.9 ± 15.0 (284)                    18.8 ± 14.5 (283)                  20.0 ± 15.3 (282)
  PASDAS, mean ± SEM (no. assessed)                                              6.09 ± 0.07 (282)                    6.05 ± 0.07 (279)                  6.04 ± 0.07 (280)
  DAPSA, mean ± SEM (no. assessed)                                               46.5 ± 1.4 (283)                     43.4 ± 1.4 (281)                   43.8 ± 1.4 (281)
  LDI                                                                                                                                                    
  Patients with score \>0 at baseline, no. (%)                                   98 (34.5)                            96 (33.8)                          90 (31.8)
  Mean ± SEM score (no. assessed)                                                164.9 ± 26.9 (98)                    147.6 ± 20.8 (96)                  138.2 ± 23.9 (90)
  SPARCC Enthesitis Index                                                                                                                                
  Patients with score \>0 at baseline, no. (%)                                   191 (67.3)                           189 (66.5)                         196 (69.3)
  Mean ± SEM score (no. assessed)                                                5.7 ± 0.3 (191)                      5.5 ± 0.3 (189)                    5.9 ± 0.3 (196)
  Psoriasis‐affected BSA, mean ± SD %                                            12.7 ± 18.8                          10.8 ± 14.7                        10.7 ± 15.6
  Patients with ≥3% affected BSA at baseline, no. (%)                            192 (67.6)                           179 (63.0)                         177 (62.5)
  Mean ± SEM % affected BSA                                                      18.1 ± 1.5                           16.4 ± 1.2                         16.4 ± 1.3
  Patients with ≥10% affected BSA at baseline, no. (%)                           99 (34.9)                            97 (34.2)                          90 (31.8)
  Mean ± SEM % affected BSA                                                      30.3 ± 2.3                           25.9 ± 1.7                         27.3 ± 2.0
  sPGA                                                                                                                                                   
  All patients, mean ± SD score                                                  2.6 ± 1.1                            2.6 ± 1.0                          2.5 ± 1.0
  Patients with ≥3% affected BSA at baseline, mean ± SEM score (no. assessed)    2.9 ± 0.1 (191)                      2.9 ± 0.1 (179)                    2.9 ± 0.1 (177)
  Patients with ≥10% affected BSA at baseline, mean ± SEM score (no. assessed)   3.2 ± 0.1 (99)                       3.1 ± 0.1 (97)                     3.3 ± 0.1 (90)
  mNAPSI                                                                                                                                                 
  Patients with score \>0 at baseline, no. (%)                                   185 (65.1)                           206 (72.5)                         197 (69.6)
  Mean ± SEM score (no. assessed)                                                3.4 ± 0.2 (183)                      3.5 ± 0.2 (205)                    3.6 ± 0.2 (195)
  HAQ DI, mean ± SEM score (no. assessed)                                        1.27 ± 0.04 (283)                    1.15 ± 0.04 (284)                  1.15 ± 0.04 (282)
  SF‐36, mean ± SEM score (no. assessed)                                                                                                                 
  Overall                                                                        80.8 ± 0.9 (282)                     82.9 ± 0.9 (284)                   83.6 ± 0.9 (282)
  MCS                                                                            45.2 ± 0.7 (282)                     45.1 ± 0.7 (284)                   46.3 ± 0.7 (282)
  PCS                                                                            35.6 ± 0.5 (282)                     37.8 ± 0.5 (284)                   37.4 ± 0.6 (282)
  SHS                                                                                                                                                    
  Total, mean ± SEM score (no. assessed)                                         2.76 ± 0.12 (269)                    2.97 ± 0.13 (273)                  2.70 ± 0.12 (274)
  Erosion score \>0, no./total no. (%)                                           223/269 (82.9)                       220/273 (80.6)                     224/274 (81.8)

PsA = psoriatic arthritis; DMARD = disease‐modifying antirheumatic drug; PASDAS = Psoriatic Arthritis Disease Activity Score; DAPSA = Disease Activity Index for Psoriatic Arthritis; LDI = Leeds Dactylitis Index; SPARCC = Spondyloarthritis Research Consortium of Canada; BSA = body surface area; sPGA = static Physician\'s Global Assessment (of psoriasis); mNAPSI = modified Nail Psoriasis Severity Index; HAQ DI = Health Assessment Questionnaire disability index; SF‐36 = Short‐Form 36 Health Survey; MCS = mental component summary; PCS = physical component summary; SHS = van der Heijde modification of the total Sharp score (of radiographic progression).

John Wiley & Sons, Ltd

The proportion of patients achieving an ACR20 response at week 24 (primary end point) was significantly greater among those receiving etanercept monotherapy compared with those receiving methotrexate monotherapy (173 \[60.9%\] of 284 patients versus 144 \[50.7%\] of 284 patients; adjusted *P* = 0.029) and significantly greater among those receiving combination therapy compared with those receiving methotrexate monotherapy (184 \[65.0%\] of 283 patients versus 144 \[50.7%\] of 284 patients; adjusted *P* = 0.005) (Figure [2](#art40851-fig-0002){ref-type="fig"} and Table [2](#art40851-tbl-0002){ref-type="table"}). The proportion of patients achieving an MDA response at week 24 (key secondary end point) was significantly greater among patients receiving etanercept monotherapy compared with those receiving methotrexate monotherapy (102 \[35.9%\] of 284 patients versus 65 \[22.9%\] of 284 patients; adjusted *P* = 0.005) and significantly greater among those receiving combination therapy compared with those receiving methotrexate monotherapy (101 \[35.7%\] of 283 patients versus 65 \[22.9%\] of 284 patients; adjusted *P* = 0.005) (Table [2](#art40851-tbl-0002){ref-type="table"} and Figure [2](#art40851-fig-0002){ref-type="fig"}).

###### 

Primary, key secondary, and select other end points at 24 weeks[a](#art40851-note-0007){ref-type="fn"}

                                                                                                   Methotrexate monotherapy (n = 284)   Etanercept monotherapy (n = 284)   *P*, etanercept monotherapy vs. methotrexate monotherapy   Combination therapy (n = 283)   *P*, combination therapy vs. methotrexate monotherapy
  ------------------------------------------------------------------------------------------------ ------------------------------------ ---------------------------------- ---------------------------------------------------------- ------------------------------- -------------------------------------------------------
  ACR improvement response, no./total (%)                                                                                                                                                                                                                             
  ACR20                                                                                            144/284 (50.7)                       173/284 (60.9)                     0.029[b](#art40851-note-0008){ref-type="fn"}               184/283 (65.0)                  0.005[b](#art40851-note-0008){ref-type="fn"}
  ACR50                                                                                            77/252 (30.6)                        114/257 (44.4)                     0.006                                                      117/256 (45.7)                  \<0.001
  ACR70                                                                                            35/253 (13.8)                        75/257 (29.2)                      \<0.001                                                    71/256 (27.7)                   \<0.001
  MDA response, no./total (%)                                                                      65/284 (22.9)                        102/284 (35.9)                     0.005[b](#art40851-note-0008){ref-type="fn"}               101/283 (35.7)                  0.005[b](#art40851-note-0008){ref-type="fn"}
  VLDA response, no./total (%)                                                                     12/252 (4.8)                         39/257 (15.2)                      \<0.001                                                    37/258 (14.3)                   \<0.001
  PASDAS, mean ± SEM change from baseline (no. assessed)                                           −1.98 ± 0.10 (246)                   −2.64 ± 0.10 (250)                 \<0.001                                                    −2.63 ± 0.11 (255)              \<0.001
  DAPSA, mean ± SEM change from baseline (no. assessed)                                            −22.6 ± 1.4 (251)                    −25.0 ± 1.3 (253)                  0.24                                                       −24.9 ± 1.4 (256)               0.23
  LDI                                                                                                                                                                                                                                                                 
  Mean ± SEM change from baseline (no. assessed)                                                   −128.8 ± 26.8 (89)                   −119.1 ± 20.7 (89)                 0.85                                                       −110.2 ± 22.7 (87)              0.68
  Resolution, no./total (%)                                                                        58/89 (65.2)                         68/89 (76.4)                       0.12                                                       69/87 (79.3)                    0.057
  SPARCC Enthesitis Index                                                                                                                                                                                                                                             
  Mean ± SEM change from baseline (no. assessed)                                                   −3.1 ± 0.3 (167)                     −3.0 ± 0.3 (173)                   0.93                                                       −2.9 ± 0.3 (179)                0.70
  Resolution, no./total (%)                                                                        72/167 (43.1)                        91/173 (52.6)                      0.11                                                       85/179 (47.5)                   0.55
  Psoriasis‐affected BSA,&error;mean ± SEM % improvement&error;from baseline (no. assessed)                                                                                                                                                                           
  Patients with ≥3% BSA affected at baseline                                                       66.1 ± 2.8 (179)                     69.8 ± 2.7 (166)                   0.49                                                       75.5 ± 3.7 (163)                0.031
  Patients with ≥10% BSA affected at baseline                                                      65.7 ± 3.7 (92)                      74.2 ± 3.3 (91)                    0.12                                                       81.6 ± 2.6 (86)                 \<0.001
  sPGA, status clear or almost&error;clear, no./total (%)[c](#art40851-note-0009){ref-type="fn"}                                                                                                                                                                      
  Patients with ≥3% BSA affected at baseline                                                       118/178 (66.3)                       120/166 (72.3)                     0.40                                                       125/161 (77.6)                  0.019
  Patients with ≥10% BSA affected at baseline                                                      54/91 (59.3)                         72/91 (79.1)                       0.012                                                      67/85 (78.8)                    0.004
  mNAPSI                                                                                                                                                                                                                                                              
  Mean ± SEM change from baseline (no. assessed)                                                   −1.1 ± 0.2 (121)                     −1.5 ± 0.2 (115)                   0.10                                                       −1.7 ± 0.2 (123)                0.020
  Patients achieving a score of 1, no./total (%)                                                   47/121 (38.8)                        50/115 (43.5)                      0.44                                                       60/123 (48.8)                   0.14
  HAQ DI, mean ± SEM change from baseline (no. assessed)                                           −0.41 ± 0.04 (252)                   −0.44 ± 0.04 (258)                 0.67                                                       −0.47 ± 0.04 (257)              0.34
  SF‐36, mean ± SEM changefrom baseline (no. assessed)                                                                                                                                                                                                                
  Total score                                                                                      9.2 ± 0.8 (253)                      10.6 ± 0.8 (256)                   0.31                                                       11.3 ± 0.9 (257)                0.11
  PCS score                                                                                        6.0 ± 0.6 (253)                      7.8 (0.6) (256)                    0.033                                                      8.0 ± 0.6 (257)                 0.015
  MCS score                                                                                        3.3 ± 0.6 (253)                      2.8 (0.6) (256)                    0.56                                                       3.3 ± 0.6 (257)                 0.97
  SHS score                                                                                                                                                                                                                                                           
  Mean ± SEM change from baseline at week 48 (no. assessed)                                        0.08 ± 0.03 (216)                    −0.04 ± 0.04 (225)                 0.014                                                      −0.01 ± 0.03 (226)              0.041
  Nonprogression at week 48, no./total (%)[d](#art40851-note-0010){ref-type="fn"}                  193/216 (89.4)                       213/225 (94.7)                     0.088                                                      214/226 (94.7)                  0.033

All end points were measured at 24 weeks, except for the van der Heijde modification of the total Sharp score (SHS) of radiographic progression, which was measured at 48 weeks. VLDA = Very Low Disease Activity; PASDAS = Psoriatic Arthritis Disease Activity Score; DAPSA = Disease Activity Index for Psoriatic Arthritis; LDI = Leeds Dactylitis Index; SPARCC = Spondyloarthritis Research Consortium of Canada; BSA = (psoriasis‐affected) body surface area; mNAPSI = modified Nail Psoriasis Severity Index; HAQ DI = Health Assessment Questionnaire disability index; SF‐36 = Short‐Form 36 Health Survey; PCS = physical component summary; MCS = mental component summary.

*P* values for the American College of Rheumatology 20% improvement (ACR20) response rates at week 24 (primary end point) and Minimal Disease Activity (MDA) response rates at week 24 (key secondary end point) were tested in a Bonferroni‐based gatekeeping procedure and stratified by body mass index category and prior nonbiologic disease‐modifying antirheumatic drug use. All other *P* values were unadjusted.

A status of clear on the static Physician\'s Global Assessment (sPGA) of psoriasis was defined as a score of 0, and a status of almost clear was defined as a score of 1. The score scale ranges from 0 (clear) to 5 (severe).

Radiographic nonprogression was defined as a change in the SHS of ≤0 from baseline to week 48.
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![Percentage of patients achieving treatment responses based on the American College of Rheumatology 20% improvement criteria (ACR20) (**A**), ACR50 (**B**), and ACR70 (**C**) and the Minimal Disease Activity (MDA) response (**D**) over time (from baseline to week 48). Data are reported as observed (patients who received rescue therapy remained in their randomized treatment arm). \* = unadjusted *P* \< 0.05; † = unadjusted *P* \< 0.01; ‡ = unadjusted *P* ≤ 0.001, versus methotrexate (MTX) monotherapy. ETN = etanercept.](ART-71-1112-g002){#art40851-fig-0002}

The proportion of patients achieving an ACR50 response at week 24 was greater for the etanercept monotherapy group compared with the methotrexate monotherapy group (114 \[44.4%\] of 257 patients versus 77 \[30.6%\] of 252 patients; unadjusted *P* = 0.006) and for the combination therapy group compared with the methotrexate monotherapy group (117 \[45.7%\] of 256 patients versus 77 \[30.6%\] of 252 patients; unadjusted *P* \< 0.001) (Table [2](#art40851-tbl-0002){ref-type="table"} and Figure [2](#art40851-fig-0002){ref-type="fig"}). Similarly, the proportion of patients achieving an ACR70 response at week 24 was greater with etanercept monotherapy compared with methotrexate monotherapy (75 \[29.2%\] of 257 patients versus 35 \[13.8%\] of 253 patients; unadjusted *P *\< 0.001) and greater with combination therapy compared with methotrexate monotherapy (71 \[27.7%\] of 256 patients versus 35 \[13.8%\] of 253; unadjusted *P* \< 0.001) (Table [2](#art40851-tbl-0002){ref-type="table"} and Figure [2](#art40851-fig-0002){ref-type="fig"}). Although not formally tested for comparison, the ACR improvement responses and MDA response were similar between the combination therapy and etanercept monotherapy arms (Table [2](#art40851-tbl-0002){ref-type="table"}). The proportions of patients achieving ACR20, ACR50, ACR70, and MDA responses at week 48 were consistent with those seen at week 24 (results for all 48‐week outcomes are shown in [Supplementary Table 3](#art40851-sup-0003){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40851/abstract>).

The mean change in SHS score from baseline at week 48 indicated that there was less radiographic progression in patients who received etanercept monotherapy compared with those who received methotrexate monotherapy (mean ± SEM change −0.04 ± 0.04 versus 0.08 ± 0.03; unadjusted *P* = 0.014), and less radiographic progression in those who received combination therapy compared with those who received methotrexate monotherapy (mean ± SEM change −0.01 ± 0.03 versus 0.08 ± 0.03; unadjusted *P* = 0.041) (Table [2](#art40851-tbl-0002){ref-type="table"}). The cumulative probability plot of the change in SHS from baseline at week 48 showed a lower likelihood of radiographic progression in the etanercept‐containing treatment arms compared with the methotrexate monotherapy arm (Figure [3](#art40851-fig-0003){ref-type="fig"}).

![Cumulative probability plot of the change from baseline in the van der Heijde modification of the total Sharp score (SHS) of radiographic progression at week 48 in the methotrexate monotherapy, etanercept monotherapy, and combination therapy study arms. At week 48, progression (change from baseline in SHS \>0) was seen in 23 patients (10.6%), 12 patients (5.3%), and 12 patients (5.3%) in the methotrexate monotherapy, etanercept monotherapy, and combination therapy arms, respectively.](ART-71-1112-g003){#art40851-fig-0003}

Consistent results were seen with rates of radiographic progression at week 48 (see [Supplementary Figure 2](#art40851-sup-0002){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40851/abstract>). Moreover, the rates of radiographic nonprogression were similar between each etanercept‐containing treatment arm.

The VLDA response at week 24 was greater in patients receiving etanercept monotherapy compared with those receiving methotrexate monotherapy (39 \[15.2%\] of 257 patients versus 12 \[4.8%\] of 252 patients; unadjusted *P* \< 0.001), and in those receiving combination therapy compared with those receiving methotrexate monotherapy (37 \[14.3%\] of 258 patients versus 12 \[4.8%\] of 252 patients; unadjusted *P* \< 0.001) (Table [2](#art40851-tbl-0002){ref-type="table"}).

Analysis of changes in disease activity levels showed that the mean improvement in the PASDAS score from baseline at week 24 was greater in the etanercept‐containing treatment arms compared with the methotrexate monotherapy arm (Table [2](#art40851-tbl-0002){ref-type="table"}). Furthermore, the mean improvement in the DAPSA score from baseline at week 24 was numerically greater in the etanercept‐containing treatment arms compared with the methotrexate monotherapy arm, but the differences were modest (Table [2](#art40851-tbl-0002){ref-type="table"}). The results for these end points were similar for both the etanercept monotherapy and combination therapy arms (Table [2](#art40851-tbl-0002){ref-type="table"}).

Although numerical trends were observed, no meaningful differences were seen in the percentage of patients who achieved clear scores on the LDI or SPARCC Enthesitis Index by week 24 between the etanercept‐containing and methotrexate monotherapy treatment arms (Table [2](#art40851-tbl-0002){ref-type="table"}). Furthermore, although not formally tested, results for the LDI and SPARCC Enthesitis Index were similar in both etanercept‐containing treatment arms (Table [2](#art40851-tbl-0002){ref-type="table"}).

In patients with ≥3% or ≥10% BSA affected by psoriasis at baseline, analyses at week 24 showed that there was greater mean percentage improvement in psoriasis‐affected BSA in patients who received combination therapy compared with those who received methotrexate monotherapy. Moreover, a greater percentage of patients in the combination therapy group had clear or almost clear sPGA scores compared with those in the methotrexate monotherapy arm (Table [2](#art40851-tbl-0002){ref-type="table"}).

The number of patients who experienced improvements in psoriasis‐affected BSA was numerically higher in the etanercept monotherapy arm compared with the methotrexate monotherapy arm. Moreover, a greater percentage of patients receiving etanercept monotherapy had clear or almost clear sPGA scores compared with patients receiving methotrexate monotherapy.

In contrast to the distributions of ACR and MDA response rates, more patients in the combination therapy group experienced numerically higher improvements in skin end points compared with patients in the etanercept monotherapy group (Table [2](#art40851-tbl-0002){ref-type="table"}). At week 24, none of the patients achieved a clear mNAPSI score, but when the percentage of patients achieving an mNAPSI score of 1 was examined, small differences between the treatment arms were seen (Table [2](#art40851-tbl-0002){ref-type="table"}).

In each of the 3 study arms, there were improvements from baseline at week 24 in the HAQ DI and SF‐36 total health function scores. Differences in the SF‐36 total score and SF‐36 mental component summary score were minimal between the study arms, but the SF‐36 physical component summary score showed a greater mean change from baseline at week 24 in the etanercept‐containing arms compared with the methotrexate monotherapy arm (Table [2](#art40851-tbl-0002){ref-type="table"}).

Over this 48‐week study, rates of adverse events, serious adverse events, and adverse events that led to discontinuation of the investigational product were similar across the 3 study arms (Table [3](#art40851-tbl-0003){ref-type="table"}). The rates of any adverse events were 212 (75.2%) of 282 patients receiving methotrexate monotherapy, 191 (67.7%) of 282 patients receiving etanercept monotherapy, and 216 (76.1%) of 284 patients receiving combination therapy. Of note, nausea occurred more commonly in the methotrexate‐containing arms (37 \[13.1%\] of 282 patients in the methotrexate monotherapy arm and 41 \[14.4%\] of 284 patients in the combination therapy arm compared with 18 \[6.4%\] of 282 patients in the etanercept monotherapy arm). Injection site reactions occurred more commonly in the etanercept‐containing arms (5 \[1.8%\] of 282 patients in the etanercept monotherapy arm and 8 \[2.8%\] of 284 patients in the combination therapy arm compared with 1 \[0.4%\] of 282 patients in the methotrexate monotherapy arm). No fatal adverse events were reported.

###### 

Summary of safety results at 48 weeks[a](#art40851-note-0011){ref-type="fn"}

                                                                         Methotrexate monotherapy (n = 282)   Etanercept monotherapy (n = 282)   Combination therapy (n = 284)
  ---------------------------------------------------------------------- ------------------------------------ ---------------------------------- -------------------------------
  Any adverse event                                                      212 (75.2)                           191 (67.7)                         216 (76.1)
  Serious adverse event[b](#art40851-note-0012){ref-type="fn"}           16 (5.7)                             19 (6.7)                           17 (6.0)
  Adverse events leading to discontinuation of investigational product   19 (6.7)                             16 (5.7)                           20 (7.0)
  Treatment‐related adverse events                                       64 (22.7)                            71 (25.2)                          79 (27.8)
  Fatal adverse events                                                   0 (0.0)                              0 (0.0)                            0 (0.0)
  Adverse events occurring in ≥5%of patients                                                                                                     
  Nausea                                                                 37 (13.1)                            18 (6.4)                           41 (14.4)
  Nasopharyngitis                                                        22 (7.8)                             21 (7.4)                           27 (9.5)
  Upper respiratory tract infection                                      21 (7.4)                             18 (6.4)                           23 (8.1)
  Diarrhea                                                               17 (6.0)                             13 (4.6)                           14 (4.9)
  Headache                                                               15 (5.3)                             12 (4.3)                           17 (6.0)
  Bronchitis                                                             9 (3.2)                              14 (5.0)                           19 (6.7)
  Vomiting                                                               15 (5.3)                             7 (2.5)                            10 (3.5)

Adverse events were categorized using the Medical Dictionary for Regulatory Activities, version 21. Values are the number (%) of patients.

The most common serious adverse events were of the system organ class infections and infestations, which occurred in 1.1% of patients in the methotrexate monotherapy arm, 2.8% of patients in the etanercept monotherapy arm, and 2.5% of patients in the combination therapy arm.
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Discussion {#art40851-sec-0013}
==========

The SEAM‐PsA trial contributes to our understanding of how best to treat patients early in the course of PsA who are naive to treatment with methotrexate and to biologic DMARDs. The results of this study demonstrate that etanercept as monotherapy and in combination with methotrexate is superior to methotrexate monotherapy when assessed according to the proportion of patients experiencing ACR20 and MDA responses (the primary and key secondary end points of the trial, respectively). The ACR50 and ACR70 responses and the PsA‐specific composite measures (VLDA and PASDAS) also showed greater efficacy with etanercept monotherapy and combination therapy compared with methotrexate monotherapy. The etanercept‐containing treatment arms also showed less radiographic progression compared with the methotrexate monotherapy arm. In general, the addition of methotrexate to etanercept did not contribute meaningfully to the overall efficacy of etanercept monotherapy, except in the case of some of the skin end points, for which combination therapy appeared to have increased efficacy.

The results of this study represent a detailed characterization of the efficacy of methotrexate monotherapy relative to a TNF inhibitor across a broad spectrum of PsA clinical manifestations in patients with early PsA. To overcome a key criticism of the MIPA trial [21](#art40851-bib-0021){ref-type="ref"}, in which the target methotrexate dosage was 15 mg/week, the SEAM‐PsA trial stipulated a target dosage of 20 mg/week and achieved mean dosages of methotrexate in the 2 methotrexate‐containing arms of \>18.8 mg/week from weeks 4 to 24.

As a comparator study, the SEAM‐PsA trial had no separate placebo arm, so the interpretation of the efficacy of methotrexate across the various clinical end points needs to be considered relative to etanercept. Nevertheless, methotrexate showed generally good efficacy across multiple domains, which is consistent with the Tight Control of PsA (TICOPA) study, which examined methotrexate monotherapy in PsA [48](#art40851-bib-0048){ref-type="ref"}. Although numerical trends were observed, no substantial differences were noted between the etanercept and methotrexate monotherapy arms in terms of enthesitis and dactylitis scores and change in psoriasis‐affected BSA from baseline (when examined among patients with ≥3% BSA involved with psoriasis at baseline). However, patients with ≥10% BSA involved with psoriasis at baseline were more likely to achieve clear or almost clear status by week 24 in the etanercept monotherapy or combination therapy groups compared with the methotrexate monotherapy group.

In addition, no clear differences in the HAQ DI or SF‐36 scores were noted between the 3 study arms, except for the SF‐36 physical component summary score, which showed a greater mean change from baseline at week 24 in the etanercept‐containing treatment arms compared with the methotrexate monotherapy arm. Overall, these results support the use of etanercept as monotherapy without the need for concomitant methotrexate, and also provide information about methotrexate when used as monotherapy.

Some limitations of this study should be noted. The study did not consider axial disease in the eligibility criteria. In addition, the study included patients with mostly polyarticular disease (with mean swollen joint counts and tender joint counts of \~12 and \~30, respectively), which limits the generalizability of the results to those patients with oligoarticular disease and/or axial involvement. While the study was designed to characterize the relative efficacy of etanercept and methotrexate, there is significant interest in the study data with regard to efficacy of methotrexate monotherapy. However, the absence of a placebo group in this study limits the ability to draw firm conclusions about the efficacy of methotrexate monotherapy.

Disease modification is an important clinical consideration in the treatment of PsA. Investigators have demonstrated the ability of etanercept to inhibit radiographic progression in PsA [49](#art40851-bib-0049){ref-type="ref"}, but the effect of methotrexate on radiographic progression has not been studied in a placebo‐controlled trial. Since the SEAM‐PsA study did not enrich for patients with radiographic evidence of PsA, only a small subset of patients, as expected, showed radiographic changes over a 48‐week period. Moreover, any differences between the methotrexate monotherapy arm and the etanercept monotherapy arm at week 48 would have been blunted by the 24.3% of patients in the methotrexate monotherapy arm who received rescue combination therapy starting at or after week 24. These results demonstrate that etanercept is associated with a lower degree of radiographic progression compared with methotrexate, and that combining methotrexate and etanercept may not have any discernible effect on radiographic progression as compared with etanercept monotherapy. Although the magnitude of the effects was small, the differences were clear for this clinically important end point. The lack of a placebo arm limits the ability to interpret the effect of methotrexate alone on radiographic progression, and these results (as for the other end points) should be interpreted relative to those in the other treatment arms.

MDA response was included as the key secondary end point in this trial to highlight the importance of more comprehensively capturing the unique clinical manifestations of PsA when compared with the "joint‐centric" ACR response measures. The MDA criteria evaluate PsA disease activity using measures of joint and entheseal inflammation, skin disease, patient‐reported outcomes, and functional disability [24](#art40851-bib-0024){ref-type="ref"}, [35](#art40851-bib-0035){ref-type="ref"}, [50](#art40851-bib-0050){ref-type="ref"}, [51](#art40851-bib-0051){ref-type="ref"}, [52](#art40851-bib-0052){ref-type="ref"}. The MDA response rates in this study were consistent with the ACR20, ACR50, and ACR70 response rates in terms of showing greater responses in the etanercept‐containing treatment arms compared with the methotrexate monotherapy arm; no additional efficacy was observed with combination therapy compared with etanercept monotherapy.

In addition to the MDA response, other PsA‐specific outcome measures were included in this study in support of the overall findings. The VLDA response has recently become a clinically relevant benchmark that utilizes the same components as the MDA but with response defined as meeting all 7 MDA criteria. PASDAS and DAPSA are additional measures (with PASDAS covering a broader spectrum of PsA manifestations) that assess a binary outcome in PsA and also provide a continuous measure of disease activity. The PASDAS scores were consistent with those seen for the ACR and MDA responses, but the DAPSA scores showed similar outcomes across all 3 study arms. Consistent with the other end points, methotrexate did not contribute additional efficacy to etanercept alone.

Many patients in this trial had a moderate‐to‐severe level of psoriasis, as assessed by the percentage of psoriasis‐affected BSA. Results with regard to the dermatologic end points showed that etanercept and methotrexate had good efficacy, with a suggestion that the combination treatment arm had slightly greater efficacy than either of the monotherapy treatment arms in terms of improvement in the percentage of psoriasis‐affected BSA, sPGA scores, and mNAPSI scores. The fact that etanercept was more effective in combination with methotrexate for the skin‐related end points is consistent with results reported in a prior study [53](#art40851-bib-0053){ref-type="ref"}; it should also be noted that etanercept monotherapy was administered at 50 mg once per week in this study, but is indicated for use at 50 mg twice per week to treat psoriasis in adults [33](#art40851-bib-0033){ref-type="ref"}.

The observed varied impact of methotrexate, both alone and as an addition to etanercept, across these individual manifestations provides insights about the potentially context‐dependent and heterogeneous drivers of PsA pathology. Taken as a whole, the SEAM‐PsA trial results are remarkably different from those of the TEMPO trial in rheumatoid arthritis [28](#art40851-bib-0028){ref-type="ref"}, in which the combination of etanercept and methotrexate was more effective than etanercept monotherapy, which underscores the pathophysiologic differences between rheumatoid arthritis and PsA [54](#art40851-bib-0054){ref-type="ref"}.

Differences among TNF inhibitors have been noted in terms of their effects on long‐term survival in patients in clinical registries, when the impact of using a TNF inhibitor as monotherapy has been compared with a TNF inhibitor in combination with methotrexate [29](#art40851-bib-0029){ref-type="ref"}, [55](#art40851-bib-0055){ref-type="ref"}. These differences should be taken into account when considering the use of TNF inhibitors as monotherapy or in combination with methotrexate. Because of patients' and physicians' concerns with regard to the tolerability and safety of methotrexate, a clear understanding of its clinical benefits, alone or in combination with TNF inhibitors, is an important aspect of clinical decision‐making. Thus, the characterization in this trial of the safety and tolerability of both methotrexate monotherapy and biologic monotherapy provides important information when considering the safety profile (including immunogenicity) associated with PsA treatment approaches.

Overall, these results provide information that is of practical value for clinical practice, in terms of both demonstrating the relative efficacy of methotrexate and etanercept and characterizing the impact of combining methotrexate and etanercept across a broad range of PsA clinical manifestations.
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